News Summary

• Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasia.
• BPH is the most common prostate disease and impacts approximately 40 million men in the United States.
• The EAU guidelines are widely regarded as one of the most rigorous and influential clinical guideline frameworks in urology globally.
• This upgrade indicates strong evidence quality and a favorable balance between benefit, harm, and patient preference, says Evangelos Liatsikos, MD, PhD.